RARE Ultragenyx
Company Analysis
Latest News
🟢 Ultragenyx is trading 5.5% up today amid a biotech-sector rally
Ultragenyx is trading at $17.55, up 5.50% amid a biotech rally; the specific intraday catalyst is unclear. - XBI rose 2.13% in regular trading; broader-market...
🔴 Ultragenyx is trading 6% down in pre-market after Q3 revenue miss and loss above consensus
Ultragenyx is trading 6.07% down at $15.62 after its November 3 earnings release and corporate update, with reports citing missed revenue estimates and a...
🔴 Ultragenyx is trading 6.2% down in after-hours trading after 20% workforce cuts and UX701 program termination
Ultragenyx is trading 6.18% lower at $15.60 in after-hours trading after its November 3 earnings release announced a roughly 20% workforce reduction and...
Ultragenyx's third quarter 2026 revenue beat estimates while company announced a 20% workforce reduction
Ultragenyx reported total revenue of $173 million for the third quarter of 2026, exceeding analyst expectations despite a slight miss on its lead product,...
Ultragenyx Wins Conditional UK Approval for Dojolvi, Its First in Europe
Ultragenyx Pharmaceutical Inc. said the UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Dojolvi...
Ultragenyx Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
For Q3 2026, Ultragenyx is expected to report a net loss of $1.15 per share on revenue of $155.6 million, with its current $52.45 share price trading well...
🟢 Ultragenyx is trading 5% up today amid a biotech-sector rally
Ultragenyx is trading at $16.92, up +5.22%, with biotech-sector strength the clearest supported context. - No verified company-specific announcement explains...
🟢 Ultragenyx is trading 5.4% up today as biotech stocks rise
Ultragenyx is trading at $15.88, up 5.37%, alongside biotech stocks as the XBI rose 2.10% during Tuesday’s regular session; no report directly attributed the...
Ultragenyx Settles Patent Litigation for DOJOLVI®, Delaying Generic Entry Until 2033
Ultragenyx Pharmaceutical Inc. has entered into a settlement agreement with Navinta LLC to resolve patent litigation concerning its drug DOJOLVI®...
Ultragenyx to Sell Priority Review Voucher for $203 Million in Cash
Ultragenyx Pharmaceutical Inc. has entered into a material agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million. The...
Ultragenyx Announces Sale of Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical Inc. has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash....
🔴 Ultragenyx is trading 5% down
Ultragenyx is trading 5.45% lower at $14.39, with no new company announcement clearly tied to the October 5 intraday decline. - The Phase 3 Aspire study in...
🟢 Ultragenyx is trading 5.8% up
Ultragenyx is trading 5.8% higher at $15.25, with no clear company-specific catalyst identified for the move. - Recent coverage centers on the FAYUVI FDA...
🔴 Ultragenyx is trading 5.32% down today amid market pressure and a pullback after gains
Ultragenyx is trading 5.32% down at $14.79 as broader risk-off sentiment weighs on equities. - Nasdaq is down 1.00% and S&P 500 is down 0.55%; biotech is...
🟢 Ultragenyx is trading 5.8% up today as investors reprice FAYUVI approval
Ultragenyx is trading 5.8% up at $15.49 as investors continue repricing the company following the September 17, 2026 FDA approval of FAYUVI, the first approved...
Ultragenyx Announces FDA Full Approval for FAYUVI™, First-Ever Gene Therapy for MPS IIIA
Ultragenyx Pharmaceutical Inc. announced it received standard full approval from the U.S. Food and Drug Administration (FDA) for FAYUVI™ (rebisufligene...
🟢 Ultragenyx is trading 11.57% up today as XBI rises amid renewed M&A optimism
Ultragenyx is trading at $14.37, up 11.57%, as biotechnology rebounds and XBI rises 2.55%. • The rebound reflects a stronger industry outlook and renewed M&A...
🟢 Ultragenyx is trading 5.5% up today amid a broad biotechnology rebound
Ultragenyx is trading 5.5% up at $13.59, alongside a broad biotechnology rebound and stronger overall risk appetite. - No new company-specific announcement...
🟢 Ultragenyx is trading 5% up today as rebound appears to reflect post-selloff trading
Ultragenyx is trading 5% up at $15.62, rebounding after its September 3, 2026 close of $14.85, when shares fell 44.03%. - The earlier collapse followed...
🔴 Ultragenyx is trading 47% down today after apazunersen fails Phase 3 Aspire trial
Ultragenyx is trading 47% down at $14.03 after apazunersen (GTX-102) failed its Phase 3 Aspire trial in Angelman syndrome. - The treatment missed both its...